Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EP-1090
- Development stage
- Phase 2
- Lead developer
- Epimmune
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
EP-1090 is a plasmid DNA vaccine composed of engineered cytotoxic T-lymphocyte (CTL) epitopes from HIV-1 designed to elicit strong, multi-epitope, cell-mediated immune responses against HIV-1. Developed originally by Epimmune and later associated with VaxOnco, this prophylactic HIV DNA vaccine encodes selected conserved CTL epitopes intended to broaden and enhance antiviral CD8+ T-cell responses, thereby improving control of HIV-1 infection or preventing acquisition when used as a vaccine. It has been evaluated in early-phase clinical trials primarily to assess safety, tolerability, immunogenicity, and antiviral activity in humans.[6][8][9][10]
- Other names
- HIV-1 CTL epitope-based DNA vaccineHIV1 CTL epitope-based DNA vaccineHIV 1 CTL epitope-based DNA vaccineHIV DNA vaccine
02
Targets
pMHC-II (Peptide-major histocompatibility complex class II complex)Major histocompatibility complex class I presenting HIV-1 cytotoxic T lymphocyte epitopes
Beyond the preview
Go deeper on EP-1090.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EP-1090.